Cargando…

Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?

Detalles Bibliográficos
Autores principales:	Hammer, Andreas, Niessner, Alexander, Sulzgruber, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682866/ https://www.ncbi.nlm.nih.gov/pubmed/37806673 http://dx.doi.org/10.1002/ehf2.14549

Ejemplares similares

Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction
por: Falco, Luigi, et al.
Publicado: (2023)

Vericiguat for Heart Failure with Reduced Ejection Fraction
por: Lombardi, Carlo Mario, et al.
Publicado: (2021)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction
por: Nakamura, Makiko, et al.
Publicado: (2023)

Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
por: Ruehs, Hauke, et al.
Publicado: (2021)

Real‐world eligibility for vericiguat in decompensated heart failure with reduced ejection fraction
por: Oh, Jaewon, et al.
Publicado: (2022)

Comment on “Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective”
por: Gandjour, Afschin
Publicado: (2022)

The Prognostic Impact of Circulating Regulatory T Lymphocytes on Mortality in Patients with Ischemic Heart Failure with Reduced Ejection Fraction
por: Hammer, Andreas, et al.
Publicado: (2020)

Vericiguat in Heart Failure with a Reduced Ejection Fraction: Patient Selection and Special Considerations
por: Kassis-George, Hayah, et al.
Publicado: (2022)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
por: Senni, Michele, et al.
Publicado: (2022)

Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event
por: Alsumali, Adnan, et al.
Publicado: (2021)

Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
por: Voors, Adriaan A., et al.
Publicado: (2021)

Evaluation of high‐sensitivity C‐reactive protein and uric acid in vericiguat‐treated patients with heart failure with reduced ejection fraction
por: Kramer, Frank, et al.
Publicado: (2020)

Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021)

Heart failure with preserved ejection fraction: A distinct heart failure phenotype?
por: Triposkiadis, Filippos, et al.
Publicado: (2022)

Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost?
por: Xanthopoulos, Andrew, et al.
Publicado: (2022)

Methodological problems in the measurement of interleukin-33 concentrations in patients with heart failure with a reduced ejection fraction
por: Keskin, Berhan, et al.
Publicado: (2019)

Chronic heart failure: the role of di vericiguat
por: Caminiti, Giuseppe, et al.
Publicado: (2023)

An increase in acute heart failure offsets the reduction in acute coronary syndrome during coronavirus disease 2019 (COVID‐19) outbreak
por: Sulzgruber, Patrick, et al.
Publicado: (2020)

Cause of Death Among Patients With Diabetes and Heart Failure With Reduced Ejection Fraction
por: Sharma, Abhinav, et al.
Publicado: (2022)

Propensity for Calcification in Serum Associates With 2-Year Cardiovascular Mortality in Ischemic Heart Failure With Reduced Ejection Fraction
por: Bojic, Marija, et al.
Publicado: (2021)

Vericiguat: A New Hope for Heart Failure Patients
por: Chiles, Raquel, et al.
Publicado: (2022)

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction
por: Nagata, Takuya, et al.
Publicado: (2023)

Emerging concepts in heart failure management and treatment: focus on vericiguat
por: Kaplinsky, Edgardo, et al.
Publicado: (2023)

The impact of CD4(+)CD28(null) T lymphocytes on atrial fibrillation: a potential pathophysiological pathway
por: Hammer, Andreas, et al.
Publicado: (2021)

Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction
por: Liu, Dan, et al.
Publicado: (2023)

Management of heart failure with reduced ejection fraction
por: Haydock, Paul M, et al.
Publicado: (2022)

Prognostic Value of Anxiety Between Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
por: Lin, Tin‐Kwang, et al.
Publicado: (2019)

Wild type transthyretin amyloidosis, a reason not to be forgotten for heart failure of preserved ejection fraction in the elderly
por: TIAN, Zhuang, et al.
Publicado: (2020)

Reply to ‘Heart failure with preserved ejection fraction and COVID‐19: which comes first, the chicken or the egg?’
por: Anker, Markus S., et al.
Publicado: (2021)

Iron deficiency correction in heart failure patients with preserved ejection fraction: a case series study
por: Cosentino, Eugenio Roberto, et al.
Publicado: (2021)

A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
por: Sahana, Urjosee, et al.
Publicado: (2023)

Efficacy and safety of vericiguat in heart failure: a meta-analysis
por: Ma, Jianhua, et al.
Publicado: (2023)

Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021)

Heart Failure with Reduced Ejection Fraction—Does Sex Matter?
por: Swaraj, Sascha, et al.
Publicado: (2021)

Heart Failure Across the Range of Mildly Reduced and Preserved Ejection Fraction in the United States
por: Greene, Stephen J., et al.
Publicado: (2023)

Stiff left atrial syndrome as another cause for heart failure with preserved ejection fraction and normal BNP levels
por: Lucas, C. M. H. B.
Publicado: (2016)

How to Improve the Cardiac Function and Clinical Outcomes in Patients with Heart Failure with a Mid-range Ejection Fraction
por: Imamura, Teruhiko
Publicado: (2021)

Occurrence of Stroke and Reduced Ejection Fraction in Patients with Chagas Disease
por: Sampaio, Elieusa e Silva, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_udrfgkvp4pc6qota9vpcbj8a7b